Jove
Visualize
Contact Us

Related Concept Videos

Hyperthyroidism II: Pathophysiology01:27

Hyperthyroidism II: Pathophysiology

Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH receptors...
Hyperthyroidism I: Introduction01:25

Hyperthyroidism I: Introduction

Hyperthyroidism is a type of thyrotoxicosis characterized by the thyroid gland's overproduction of the thyroid hormones triiodothyronine (T3) and thyroxine (T4). This hormone excess increases the basal metabolic rate and enhances sensitivity to catecholamines.DiagnosisDiagnosis is based on clinical features and biochemical testing. It typically shows suppressed thyroid-stimulating hormone (TSH) levels below 0.4 mIU/L, with elevated free T3 and/or T4. Additional tests, including thyroid...
Hypothyroidism II: Pathophysiology01:23

Hypothyroidism II: Pathophysiology

Hypothyroidism is a disorder characterized by insufficient production of thyroid hormones, which regulate metabolism, energy balance, and multiple organ systems.TypesHypothyroidism is classified based on the level of dysfunction. Primary hypothyroidism results from intrinsic thyroid gland dysfunction, causing reduced hormone production despite normal or increased stimulation. Secondary hypothyroidism arises from inadequate thyroid-stimulating hormone (TSH) secretion by the pituitary. Tertiary...
Synthesis and Regulation of Thyroid Hormones01:20

Synthesis and Regulation of Thyroid Hormones

Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The iodine is then...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Oral treatment of type 2 diabetes mellitus].

Deutsche medizinische Wochenschrift (1946)·2012
Same author

Association between serum ferritin and the insulin resistance syndrome in a representative population.

European journal of endocrinology·2006
Same author

[Postalimentary hypoglycaemia in post-gastrectomy late dumping syndrome].

Deutsche medizinische Wochenschrift (1946)·2005
Same author

Definition and characterization of relative hypo- and hyperleptinemia in a large Caucasian population.

The Journal of endocrinology·2002
Same author

Orofacial granulomatosis as initial manifestation of Crohn's disease: a report of two cases.

European journal of gastroenterology & hepatology·2002
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jun 28, 2026

Mixed Reality Assisted Radical Endoscopic Thyroidectomy
08:06

Mixed Reality Assisted Radical Endoscopic Thyroidectomy

Published on: January 31, 2025

[Prevention and multimodal therapy of hyperthyroidism].

K-D Palitzsch1

  • 1Klinik für Endokrinologie, Diabetologie, Angiologie und Innere Medizin, Klinikum Neuperlach, Städtisches Klinikum München GmbH, München, Deutschland. kd.palitzsch@kh-neuperlach.de

Der Internist
|October 24, 2008
PubMed
Summary
This summary is machine-generated.

Hyperthyroidism, or overactive thyroid, increases risks like atrial fibrillation and cardiovascular death, particularly in older adults. Avoiding iodine and unnecessary TSH suppressive therapy can help prevent this condition.

Related Experiment Videos

Last Updated: Jun 28, 2026

Mixed Reality Assisted Radical Endoscopic Thyroidectomy
08:06

Mixed Reality Assisted Radical Endoscopic Thyroidectomy

Published on: January 31, 2025

Area of Science:

  • Endocrinology
  • Cardiology

Context:

  • Subclinical and overt hyperthyroidism are linked to adverse outcomes, including atrial fibrillation and cardiovascular mortality, especially in the elderly.
  • Iodine-containing medications and contrast agents can precipitate hyperthyroidism.

Purpose:

  • To review the clinical outcomes associated with hyperthyroidism and provide recommendations for its prevention and management.
  • To highlight the risks of TSH suppressive therapy in endemic goiter and differentiated thyroid carcinoma.

Summary:

  • Hyperthyroidism is associated with significant health risks, particularly in older individuals.
  • Preventive measures include judicious use of iodine and contrast agents.
  • TSH suppressive therapy is generally not recommended for endemic goiter or low-risk thyroid cancer due to the risk of inducing hyperthyroidism.
  • Overt hyperthyroidism management depends on the underlying cause, utilizing antithyroid drugs, radioiodine, or surgery.

Impact:

  • Informing clinical practice to reduce hyperthyroidism incidence and associated complications.
  • Guiding therapeutic decisions regarding TSH suppressive therapy and overt hyperthyroidism treatment.
  • Improving patient outcomes by mitigating risks of atrial fibrillation and cardiovascular mortality.